AzTrials
AzTrials

PreDiabetesPhase 4NCT07462078

The Effect of Lifestyle Modification on the Risk of Prediabetes Among Patients Attending Outpatient Clinic.

A Phase 4 study testing Lifestyle modification in people with PreDiabetes, run by Kasr El Aini Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Diabetes mellitus is a major global health challenge, with type 2 diabetes (T2DM) accounting for nearly 90% of all cases worldwide. In Egypt, diabetes prevalence among adults is high (15.2%), with approximately 10.9 million people currently affected and projections estimating a rise to 13 million by 2030, placing… Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
PreDiabetes
What is being tested?
Lifestyle modification
Could I receive a placebo?
No, everyone receives an active treatment
How many people
124 participants
Where
1 siteEgypt
Study dates
25 Sep 2024to 2 Jun 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age from 18 to 70 years old.
  • Both sexes.
  • Read and write.
  • Prediabetic as detected by:
  • FINDRISC score of ≥ 7.
  • Confirmed by Fasting blood glucose of 100-125 mg/d L, OGTT of 140 -200 -mg/dL and Hba1c of 5.7-6.4 %
  • Have a smart mobile.

Who cannot join

  • Known diabetes mellitus patients.
  • Known Malabsorption syndrome patients.
  • Known allergic patients to some food items such as lactose intolerance.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Research Institute of Medical Entomology

    Giza, Doki, 202

Other trials in Egypt

About this study

Official title: The Effect of Lifestyle Modification on the Risk of Prediabetes Among Patients Attending Outpatient Clinic of Research Institute of Medical Entomology.

Diabetes mellitus is a major global health challenge, with type 2 diabetes (T2DM) accounting for nearly 90% of all cases worldwide. In Egypt, diabetes prevalence among adults is high (15.2%), with approximately 10.9 million people currently affected and projections estimating a rise to 13 million by 2030, placing Egypt among the top ten countries worldwide for diabetes prevalence. Alarmingly, a large proportion of diabetes and most prediabetes cases remain undiagnosed.

Prediabetes is a common, asymptomatic, and reversible condition that precedes T2DM and is characterized by elevated blood glucose levels not meeting diagnostic thresholds for diabetes. Diagnostic criteria include impaired fasting plasma glucose, impaired glucose tolerance, and elevated HbA1c. Globally, prediabetes affects nearly one-third of adults, and in Egypt its prevalence ranges from 21-24% in community and occupational settings. Individuals with prediabetes face a significantly increased risk of progressing to T2DM, cardiovascular disease, and mortality, with up to 70% developing diabetes during their lifetime if left untreated.

Read more

Early identification of prediabetes is essential and cost-effective. Non-invasive screening tools such as the Finnish Diabetes Risk Score (FINDRISC) provide a practical method for identifying high-risk individuals, who can then undergo confirmatory blood testing. Lifestyle modification is the cornerstone of prediabetes management and is more effective than pharmacological therapy alone. Evidence shows that modest weight loss, increased physical activity, and dietary improvements significantly reduce diabetes incidence and improve glycemic parameters.

Structured lifestyle programs, particularly the Diabetes Prevention Program (DPP), have demonstrated substantial benefits through achieving at least 7% weight loss and 150 minutes of moderate physical activity per week. Establishing nationwide screening and lifestyle intervention programs in Egypt is strongly recommended to reduce the burden of diabetes. Local implementation initiatives provide critical evidence to support the scalability and effectiveness of such preventive strategies.

Read the detailed description

Diabetes is a worldwide epidemic and Type 2 DM (T2DM) accounts for nearly 90% of all diabetes cases worldwide. In Egypt, the prevalence of DM among adults was reported to be 15.2%. Recently it was estimated that 10.9 million had diabetes and this number is expected to rise to 13 million by 2030. This makes Egypt rank in the 10th position among countries with highest prevalence of DM. Furthermore, reports indicate that 43% of patients with diabetes and most patients with prediabetes in Egypt are likely undiagnosed.

Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. IT doesn't usually appear all of a sudden; many people have a long, slow, invisible lead-in to it called prediabetes. Prediabetes precedes T2DM, and in most of the cases, it ultimately leads to the development of diabetes.

There are no clear symptoms of prediabetes; Some people with prediabetes may have some of the symptoms of diabetes or even problems from diabetes already. The single sign of prediabetes is elevated blood glucose on a blood test that is not high enough to be classified as type 2 diabetes mellitus. Criteria for diagnosing Prediabetes are elevated Glycated hemoglobin (Hba1C), impaired fasting plasma glucose (IFPG), impaired glucose tolerance (IGT), and both IFPG together with IGT. Cutoff levels indicating prediabetes are Hba1c of 5.7-6.4%, Fasting blood glucose of 100-125 mg/dL and 2-hour Oral Glucose Tolerance Test (OGTT) of 140-199 mg/dL. The 2-hour OGTT is laborious to perform, and results are inconsistent. FPG is commonly used in both clinical and epidemiological studies, but patients need to fast overnight. HbA1c detection is more convenient, more accurate with less pre-analytical and analytical variability; its use to diagnose diabetes has been widely recommended.

The prevalence of prediabetes is high and is increasing rapidly in all parts of the world. It was reported to affect 1 in 3 adults in the US and approximately 720 million individuals worldwide. In Egypt, the prevalence of prediabetes in a community-based sample was found to be 21.7%. In a convenience sample of 352 employees at Faculty of Medicine, Ain Shams University, 36% were at high risk and 65.4% of high-risk participants were confirmed to be Prediabetic (23.6% of total sample). It was slightly lower among adults attending PHC in Al Bahah city, KSA (20%, around 21% in males and 19% in females of all ages).

The main risk factors that strongly influence abnormal glycemic level are age, being physically inactive, previous history of abnormal glycemic level and waist circumference. Other factors include aging, smoking, obesity (central obesity), hypertension, and a family history of DM . Prediabetes is associated with increased risk of diabetes, cardiovascular events, and mortality. Approximately 10% of people with prediabetes progress to having diabetes each year. The progression of prediabetes to overt T2DM is around 25% within 3 to 5 years and as many as 70% of them will be manifested with diabetes within their lifetime. Therefore, identifying those individuals with prediabetes is crucial and cost-effective for reducing the incidence of diabetes.

Pre-diabetes is a reversible condition. Early detection of prediabetes through screening is paramount for providing timely intervention and support, reducing the risk of T2DM and associated health complications. The screening process for prediabetes is the same as for type 2 diabetes and it relies on clinical risk factors. Recently, many trials have been made to develop simple, fast, non-invasive, and practical screening tools for prediabetes. The Finnish Diabetes Risk Score (FINDRISC) is a noninvasive and practical tool originally planned in Finland to recognize individuals at high risk of T2DM, without the required laboratory tests. The FINDRISC questionnaire was used by registered dietitians as part of the regular process during nutritional evaluation. High risk individuals detected by the screening test are subjected to blood glucose testing to confirm the diagnosis of prediabetes.

The First-line therapy for prediabetes is lifestyle modification that includes weight loss and exercise or metformin. Lifestyle modification is associated with a larger benefit than metformin. Lifestyle interventions decreased the incidence risk ratio of type 2 diabetes by 25% (0·75 [95% CI 0·61 to 0·91]), and reduced the levels of Hba1C by 0·15% [-0·25 to -0·05], fasting plasma glucose by 3·44 mg/dL [-4·72 to -2·17], and 2-hr glucose tolerance by 4·18 mg/dL [-7·35 to -1·02]. Adopting a well-balanced diet, staying active, controlling your weight can put you in control, enabling you to arrest or even reverse the process.

The behavioral lifestyle intervention, quietly known as diabetes prevention program (DPP), has turned into the standard for powerful strategies to prevent T2DM by overweight management, favorable diet planning and physical activity achievements. The two major targets of the DPP, behavioral, lifestyle involvement was to enhance and maintain a minimum of 7% weight loss and 150 min of physical exercise per week like in strength to brisk walking.

Lifestyle, especially diet, forms the actual foundation of treatment to enhance blood glucose, lipid profile and blood pressure level, and decrease the rate of cardiovascular morbidity and mortality in those individuals.

The general goal of nutrition intervention in people with prediabetes or DM2 is to help them improve their nutrition habits to prevent and/or delay the disease, enhance their metabolic condition, treat associated complications, and control or enhance their quality of life. Weight loss is related to enhancing glycemic control: the larger the weight loss, the greater the improvement in Hba1C. Nutrition counseling of the prediabetics regarding dietary and lifestyle modification is recommended so as to improve their metabolic control, thus preventing them from being diabetics.

Physical activity is a safe, and cost-effective approach, which can help people with prediabetes to obtain different goals, as reducing metabolic syndrome and managing obesity.

People who lose about 7% of their weight and do physical activity (30 min/day) increase insulin sensitivity and have > 90% risk reductions of diabetes.

The establishment of a nationwide program in Egypt for early detection of undiagnosed DM and those at risk of developing DM with comprehensive intervention measures for lifestyle modification was highly recommended. Implementation of risk screening and lifestyle changes for those at risk at the Research Institute of Medical Entomology is a step forward to provide evidence for the large-scale implementation of such effective intervention.

Conditions
PreDiabetes
Being tested
Lifestyle modification
Medical subject headings
Prediabetic State

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lifestyle modificationBehavioural

    Also called Drug: Metformin

    A combination of interactive counseling, visual educational materials, audio reminders and mobile-based support tools was used to enhance participants' understanding, motivation and adherence to lifestyle modification recommendations. Printed visual aids, illustrated dietary guides, anthropometric feedback charts and physical activity posters were used during counseling sessions. Audio messages and phone reminders were delivered to reinforce behavioral change and improve compliance throughout the intervention period.

Study groups in NCT07462078
Study groupRoleWhat they receive
InterventionExperimentalEach patient in the intervention group had received 6 sessions according to settled appointments to check the adherence of the patient to the nutrition plan, physical activity and adherence to Metformin (if prescribbed)
Receives: Behavioral: Lifestyle modification
Non-interventionNo interventionnon-intervention group received nutrition education session at the end of the study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. FIND risk score questionnaire

    Early detection of patients at risk of diabetes (Prediabetic) using FIND risk score questionnaire

    Measured: 2 months

Secondary outcomes (9)
  1. Fasting blood glucose measurement

    Prediabetic state using Fasting blood glucose in mg/dl.

    Measured: 6 months

  2. Knowledge, attitude and Practice questionnaire

    KAP evaluation using KAP questionnaire.

    Measured: 6 months

  3. Assessment of weight reduction

    By measuring BMI (weight and height will be combined to report BMI in kg/m^2)

    Measured: 6 months

  4. Compliance to nutrition plan

    Assessing compliance to diet plan in intervention group using a questionnaire

    Measured: 6 months

  5. Compliance to Metformin assessment

    Assessing compliance to Metformin through assessment of rate of intake of the medication by the selected participants in the intervention group how meet the criteria of use of metformin.

    Measured: 6 months

  6. Assessment of lifestyle quality

    Using a questionnaire to assess nutritional habits and physical activity

    Measured: 6 months

  7. Glucose tolerance test measurement

    Measuring Prediabetic state using Glucose tolerance test in mg/dL

    Measured: 6 months

  8. Glycated hemoglobin measurement

    Measuring Prediabetic state using HbA1c

    Measured: 6 months

  9. Assessment of change of Waist circumferance

    Measurement of Waist circumferance in cm to follow up the fat reduction

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Mar 2026
  2. Study start25 Sep 2024
  3. Primary completion2 May 2025
  4. Study completion2 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
124 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07462078
Sponsor's protocol ID
MD-87-2024
Status last verified
Mar 2026
First submitted
23 Feb 2026
Last updated
10 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Lifestyle modification in people with PreDiabetes, run by Kasr El Aini Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

FIND risk score questionnaire (time frame: 2 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in